5-Methoxy-1H-pyrazolo[4,3-b]pyridine, 95.0%, 250mg

4-[3-(Trifluoromethyl)phenyl]piperidin-4-ol hydrochloride, 97.0%, 1g

3-(4,4,4-trifluoro-3-hydroxybut-2-enoyl)benzonitrile, 95%, 250mg

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-5-((tert-butoxycarbonyl)amino)pentanoic acid, 97%, 10g

(R)-Methyl 5-(4-(6-benzyl-4,5-dimethylpyridazin-3-yl)-2-methylpiperazin-1-yl)pyrazine-2-carboxylate, 98%, 100mg

Methyl cis-13-Docosenoate>90.0%(GC)500mL

(E)-4-(3,5-Dimethoxystyryl)-1,2-dimethoxybenzene, 97%, 1g

(4-Methoxy-phenyl)-morpholin-4-yl-acetic acid; hydrochloride, 95.0%, 5g

Triethylene Glycol Monomethyl Ether>98.0%(GC)25mL

N-(2,5-dichlorophenyl)-3-oxobutanamide, 98+%, 5g

(3-(tert-Butoxy)-2',6'-diisopropyl-6-methoxy-[1,1'-biphenyl]-2-yl)dicyclohexylphosphane, 98%, 5g

1-ethyl-1H-pyrazole-4-carbonitrile, 95.0%, 10g

1,3-Cyclohexanediamine (cis- and trans- mixture)>95.0%(GC)(T)5mL